Trial Profile
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Aug 2023
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Docetaxel (Primary) ; Erlotinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 18 Aug 2023 Planned End Date changed from 30 Sep 2023 to 31 Dec 2024.
- 18 Aug 2023 Planned primary completion date changed from 30 Sep 2023 to 31 Dec 2024.
- 21 Jul 2022 Planned End Date changed from 1 Sep 2021 to 1 Sep 2023.